KRAS and pancreatic neoplasm: The aim of this study was to determine the cytotoxicity of ECT using BLM or CDDP and to evaluate the interactions of ECT with the targeted drug sotorasib in KRAS G12C-mutated MIA PaCa-2 and KRAS G12D-mutated PANC-1 pancreatic cancer cell lines [24].